Im­pel Phar­ma con­sid­ers bank­rupt­cy, as­set sales de­spite mi­graine nasal spray quar­ter­ly rev­enue jump

There is “sub­stan­tial doubt” that Im­pel Phar­ma­ceu­ti­cals can con­tin­ue, and the biotech, which has one mi­graine nasal spray treat­ment, is con­sid­er­ing bank­rupt­cy or sell­ing off its as­sets, ac­cord­ing to SEC fil­ings.

Im­pel re­port­ed prod­uct rev­enue of $6.6 mil­lion for the sec­ond quar­ter — a jump from $2.8 mil­lion at the same time last year thanks to in­creased sales of its nasal spray — but it’s not enough to keep up with the near­ly $20 mil­lion it spent on com­mer­cial op­er­a­tions and mar­ket­ing the drug dur­ing the quar­ter.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.